Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.

about

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).

P2860

Q47663622-A3365C97-A46E-4A34-BBF4-E52EE3EE274D

P2860

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.

Item

http://www.wikidata.org/entity/Q47109682

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cost minimization analysis of ...... sitive breast cancer in Spain.

@en

Cost minimization analysis of ...... sitive breast cancer in Spain.

@nl

type

Item

label

Cost minimization analysis of ...... sitive breast cancer in Spain.

@en

Cost minimization analysis of ...... sitive breast cancer in Spain.

@nl

prefLabel

Cost minimization analysis of ...... sitive breast cancer in Spain.

@en

Cost minimization analysis of ...... sitive breast cancer in Spain.

@nl

P1476

Cost minimization analysis of ...... ositive breast cancer in Spain

@en

P2093

D López

http://www.w3.org/2001/XMLSchema#string

G Lopez-Vivanco

http://www.w3.org/2001/XMLSchema#string

J De la Haba-Rodríguez

http://www.w3.org/2001/XMLSchema#string

J Salvador

http://www.w3.org/2001/XMLSchema#string

M De Salas-Cansado

http://www.w3.org/2001/XMLSchema#string

R Diez

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers

Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada--a time and motion study.

Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices

Cancer care and residents' working hours in oncology and hematology departments: an observational real-time study in German hospitals.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.

[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study].

P2888

s12094-017-1684-4

P304

1454-1461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-017-1684-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

B Navarro

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28577152

http://www.w3.org/2001/XMLSchema#string

P932

5700215

http://www.w3.org/2001/XMLSchema#string

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.

about

P2860

P2860

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932